Press Release : ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases

 
   - Company forms international consortium with ProteoGenix SAS and 
Amsterdam UMC 
 
   Schlieren (Zurich Area), Switzerland -- April 12, 2021 -- ImmunOs 
Therapeutics AG, a Swiss bio-technology company developing a new class 
of biologics for the treatment of cancer and autoimmune diseases, 
announced today that is has received public funding from the European 
Union's 
https://www.globenewswire.com/Tracker?data=0INCGpYOwWJZZmopXgpa8C4WLH7TQGtV97UbO-bYhcHnrUloMENXzsb-wpUuH85xVbb_eV0259cX7Fq00azrmAKT5ugwMf_WaSxTDFQ0-llDvO_po3RBuoAwOEtWlRmDrvxcsNWAwv5RHCQZKYnkYg== 
Eurostars-2 Programme and the Swiss Innovation Agency 
https://www.globenewswire.com/Tracker?data=vkinDJVYSSGPbk8ZIVxm9tRW0vgi6CUrq37Kl-p8qbd5DyKnSw5oZkPYYFR-4R23zKk0Zl2uAJr9tF8ofSLYdVGmhHDcENS9z8MxxE3CQfw= 
Innosuisse. The funds have been granted for the development of a 
pioneering HLA-open conformer-specific antibody to treat chronic 
inflammatory rheumatic diseases. Research will be conducted by a 
consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam 
University Medical Centres (Amsterdam, The Netherlands). 
 
   "The competitive funding underlines the innovative potential of our 
approach to develop HLA-based therapeutics addressing multiple targets 
via a single fusion protein," said Sean R. Smith, CEO of ImmunOs 
Therapeutics AG. "The goal of the consortium is the delivery of OCi, a 
novel monoclonal antibody to treat immune-mediated inflammatory diseases 
based on our technology platform. We plan to show our proof-of-concept 
in spondyloarthritis treatment. OCi will target a causative mechanism of 
inflammation. It works upstream of all current therapies that only 
30-50% of patients respond to." 
 
   "The OCi mAb is a new product with a completely novel mechanism of 
action ensuring superior safety and efficacy," said Dr. Osiris Marroquin 
Belaunzaran, CSO of ImmunOs. "The new antibody is expected to work in a 
large variety of immune-mediated inflammatory diseases where HLA-OCs 
trigger disease. The consortium is planning to develop OCi for psoriasis 
and inflammatory bowel disease once we achieve in vivo proof-of-concept 
in spondyloarthritis." 
 
   Within the consortium, ProteoGenix, a leader in the field of molecular 
immunology with 50 active antibody development projects and the largest 
human naïve phage display library available in Europe, will 
optimize its phage display technology for the HLA mAb development. 
 
   "We are thrilled about the opportunity to partner with ImmunOs 
Therapeutics AG and Amsterdam UMC in this challenging project," said 
Philippe Funfrock, CEO of ProteoGenix. "Optimizing our phage display 
platform for HLA mAb development will certainly serve as a basis for the 
development of immunotherapies targeting other equally complex 
inflammatory diseases using completely animal-free approaches." 
 
   Amsterdam UMC is a leading medical centre and translational research 
institution. The department of Clinical Immunology and Rheumatology 
specializes in autoimmune and immune-mediated inflammatory diseases. 
Among others, it will contribute its animal model of spondyloarthritis, 
including know-how on treatment regimens, phenotype/tissue and HLA 
expression and TCR repertoire analysis and provide access to an 
internationally recognized pool of KOLs with specific expertise on 
spondyloarthritis and other immune-mediated inflammatory diseases. 
 
   ### 
 
   About ImmunOs Therapeutics AG 
 
   ImmunOs Therapeutics AG focuses on the development of a new class of 
biologic therapeutics for the treatment of cancer and autoimmune 
diseases. The Company has established a proprietary R&D platform for the 
development of HLA-based therapeutics addressing multiple targets via a 
single fusion protein. Its novel compounds are fully human and modulate 
the innate immune system. ImmunOs Therapeutics' lead program is a 
multi-functional fusion protein that blocks specific LILRB (leukocyte 
immunoglobulin-like) receptors and activates anti-tumor responses. 
 
   ImmunOs Therapeutics AG is supported by top-tier investors such as 
Pfizer Ventures, BioMed Partners, Redalpine, Schroder Adveq, Wille 
Finance AG, BERNINA BioInvest Ltd and UZH Life Sciences Fund as well as 
undisclosed private investors. 
 
   The Company is a spin-off from the Universities of Zurich and Basel and 
based in Schlieren, Switzerland. 
 
   For more information, please visit 
https://www.globenewswire.com/Tracker?data=3NbzGMfQW2sG23BX7V7P1Io-hI9ZQSPTqhcCbzcDbRBUtompxzH-cLPQx7URRD0tYB484osIEVUtHTlKtEYZEtLC_FTp0PZh6niEVqJYjGYuXsfjxcGOp8RgpgfavklQ 
www.immunostherapeutics.com 
 
   About ProteoGenix 
 
   ProteoGenix is a biotech contract research organization (CRO) providing 
flexible end-to-end solutions for the discovery and development of 
life-saving biologics, precision diagnostic tools, and robust reagents 
for research. As a global leader in antibody, protein, peptide, and gene 
production, ProteoGenix aims at fostering the development of 
next-generation immunotherapies by leveraging the power of phage display 
technologies and combining antibody development with a strong focus on 
developability. For more information, please visit 
https://www.globenewswire.com/Tracker?data=3NbzGMfQW2sG23BX7V7P1J8ZRaVWL4jNtO22oKoDx8GLe0q7O2z3h2Ywpn40w13HcDDW9yTucZO7eIkf0Is4aI-8DWPtEqmVDGsivF7bbUA= 
www.proteogenix.science. 
 
   About Amsterdam UMC 
 
   Amsterdam UMC, merged in 2018 from the Academic Medical Center (AMC) and 
the VU University Medical Center (VUmc), is a leading medical centre 
that combines complex patient care, scientific research and education. 
The 8 research institutes of Amsterdam UMC focus on specializations like 
Infection & Immunity, Cardiovascular Sciences and Neuroscience. For more 
information, please visit 
https://www.globenewswire.com/Tracker?data=3NbzGMfQW2sG23BX7V7P1B87Y4PY9JfoBOtRolPfZyeDFk73Sdk_li-F0GggrA9qThctgsIyeh4ApEextc661fDy3fDuf_uHW0YSeHkWT8w= 
www.amsterdamumc.com. 
 
   Company Contact 
 
   ImmunOs Therapeutics AG 
 
   Wagistrasse 14 
 
   8952 Schlieren (Zurich Area), Switzerland 
 
   https://www.globenewswire.com/Tracker?data=yczkOdmpHhUN0Hhk0uwoesxeTGUP3ZZbwmsOJpC7vyPAsDz6awsgkpHrBg3hl-KHyFcFIluOtf3Tf4n_9CgOxDlpoOZi90IiLCPHM7Dn2nT7fb_8vJLQSZ2YIF9T2y1U 
[e-mail] 
 
   Media Inquiries 
 
   akampion 
 
   Dr. Ludger Wess / Ines-Regina Buth 
 
   Managing Partners 
 
   [e-mail] 
 
   Tel. [phone] / 
 
   Tel. [phone] 
 
 
 
 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

April 12, 2021 03:45 ET (07:45 GMT)